Financial Counselors Inc. Has $659,000 Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

Financial Counselors Inc. boosted its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 14.1% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 10,132 shares of the biopharmaceutical company’s stock after acquiring an additional 1,255 shares during the quarter. Financial Counselors Inc.’s holdings in Gilead Sciences were worth $659,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently modified their holdings of GILD. Lenox Wealth Management Inc. increased its holdings in Gilead Sciences by 1.8% in the first quarter. Lenox Wealth Management Inc. now owns 9,059 shares of the biopharmaceutical company’s stock valued at $589,000 after buying an additional 156 shares during the last quarter. Vectors Research Management LLC grew its holdings in shares of Gilead Sciences by 6.3% during the fourth quarter. Vectors Research Management LLC now owns 2,651 shares of the biopharmaceutical company’s stock valued at $166,000 after purchasing an additional 157 shares during the last quarter. Creative Financial Designs Inc. ADV grew its holdings in shares of Gilead Sciences by 55.9% during the first quarter. Creative Financial Designs Inc. ADV now owns 460 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 165 shares during the last quarter. Rathbone Brothers plc grew its holdings in shares of Gilead Sciences by 3.1% during the first quarter. Rathbone Brothers plc now owns 5,547 shares of the biopharmaceutical company’s stock valued at $361,000 after purchasing an additional 167 shares during the last quarter. Finally, Somerset Trust Co grew its holdings in shares of Gilead Sciences by 1.4% during the first quarter. Somerset Trust Co now owns 13,437 shares of the biopharmaceutical company’s stock valued at $874,000 after purchasing an additional 188 shares during the last quarter. Hedge funds and other institutional investors own 78.68% of the company’s stock.

Shares of NASDAQ:GILD traded up $0.27 on Monday, reaching $67.83. 4,486,434 shares of the company traded hands, compared to its average volume of 7,122,751. The firm has a 50 day simple moving average of $66.26. The company has a debt-to-equity ratio of 1.09, a current ratio of 3.62 and a quick ratio of 3.53. Gilead Sciences, Inc. has a fifty-two week low of $60.32 and a fifty-two week high of $79.61. The stock has a market cap of $87.13 billion, a PE ratio of 11.03, a PEG ratio of 3.15 and a beta of 1.12.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, May 2nd. The biopharmaceutical company reported $1.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.53 by $0.23. Gilead Sciences had a net margin of 26.40% and a return on equity of 37.98%. The company had revenue of $5.28 billion for the quarter, compared to the consensus estimate of $5.29 billion. During the same period in the previous year, the business earned $1.48 EPS. The company’s revenue was up 3.8% on a year-over-year basis. As a group, research analysts forecast that Gilead Sciences, Inc. will post 6.6 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which was paid on Thursday, June 27th. Stockholders of record on Friday, June 14th were paid a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 3.72%. The ex-dividend date was Thursday, June 13th. Gilead Sciences’s dividend payout ratio (DPR) is presently 40.98%.

In related news, Director John Francis Cogan sold 2,868 shares of the company’s stock in a transaction on Wednesday, May 1st. The shares were sold at an average price of $64.89, for a total value of $186,104.52. Following the completion of the sale, the director now directly owns 57,728 shares in the company, valued at $3,745,969.92. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Brett A. Pletcher sold 5,816 shares of the company’s stock in a transaction on Tuesday, June 18th. The stock was sold at an average price of $68.75, for a total transaction of $399,850.00. Following the completion of the sale, the executive vice president now owns 27,198 shares of the company’s stock, valued at $1,869,862.50. The disclosure for this sale can be found here. Insiders sold 19,484 shares of company stock worth $1,290,142 over the last ninety days. 0.20% of the stock is currently owned by company insiders.

Several equities analysts have recently commented on the company. UBS Group raised Gilead Sciences from a “neutral” rating to a “buy” rating and upped their target price for the company from $75.00 to $77.00 in a report on Wednesday, April 10th. Zacks Investment Research upgraded Gilead Sciences from a “sell” rating to a “hold” rating in a research report on Tuesday, April 9th. BidaskClub upgraded Gilead Sciences from a “sell” rating to a “hold” rating in a research report on Friday, May 3rd. Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a research report on Monday, May 6th. Finally, JPMorgan Chase & Co. restated a “buy” rating and issued a $87.00 target price on shares of Gilead Sciences in a research report on Tuesday, May 7th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and fifteen have assigned a buy rating to the stock. Gilead Sciences currently has a consensus rating of “Buy” and an average price target of $79.54.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

Read More: How does the Federal Reserve determine interest rates?

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.